Bicara presents data from Phase 1/1b dose expansion cohort of ficerafusp alfa

Bicara Therapeutics (BCAX) announced the presentation of data from the Phase 1/1b dose expansion cohort of ficerafusp alfa in combination with pembrolizumab in patients with second line or later squamous cancer of the anal canal, SCAC. The results were presented in a poster session during the 2025 ASCO Gastrointestinal Cancers Symposium on Saturday, January 25, 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, and is being evaluated in multiple solid tumor types.